| __timestamp | Evotec SE | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 17990000 | 22570000 |
| Thursday, January 1, 2015 | 25166000 | 24378000 |
| Friday, January 1, 2016 | 27013000 | 26621000 |
| Sunday, January 1, 2017 | 42383000 | 28653000 |
| Monday, January 1, 2018 | 57012000 | 37734000 |
| Tuesday, January 1, 2019 | 66546000 | 41884000 |
| Wednesday, January 1, 2020 | 77238000 | 64435000 |
| Friday, January 1, 2021 | 105445000 | 57483000 |
| Saturday, January 1, 2022 | 156190000 | 70062000 |
| Sunday, January 1, 2023 | 169610000 | 52790000 |
In pursuit of knowledge
In the competitive landscape of the pharmaceutical industry, understanding financial trends is crucial. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of Ligand Pharmaceuticals Incorporated and Evotec SE from 2014 to 2023. Over this period, Evotec SE's SG&A expenses surged by an impressive 843%, reflecting its aggressive expansion and operational scaling. In contrast, Ligand Pharmaceuticals saw a more modest increase of 134%, indicating a steady but less aggressive growth strategy.
These trends highlight differing strategic approaches, with Evotec SE focusing on rapid expansion and Ligand Pharmaceuticals maintaining a more conservative growth path.
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Evotec SE
Selling, General, and Administrative Costs: Exelixis, Inc. vs Ligand Pharmaceuticals Incorporated
Blueprint Medicines Corporation and Evotec SE: SG&A Spending Patterns Compared
Ionis Pharmaceuticals, Inc. vs Evotec SE: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Evotec SE
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: HUTCHMED (China) Limited vs Evotec SE
Cost Management Insights: SG&A Expenses for Ligand Pharmaceuticals Incorporated and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Agios Pharmaceuticals, Inc.
Ligand Pharmaceuticals Incorporated or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Evotec SE or MiMedx Group, Inc.